secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001453687-26-000063
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027
--------------------------------------------------------------------------------

- Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.
- R&D expenses rose to $58.0M from $45.1M, driven by Phase 3 AURORA trial and headcount growth.
- Cash, equivalents and restricted cash of $126.9M expected to support operations into mid-2027, including AURORA completion.
- Phase 3 AURORA trial for Descartes-08 in myasthenia gravis on track to enroll ~100 patients; Phase 2 TRITON in myositis IND accepted, initiation expected 1H26.
- Board changes: Adrian Bot appointed in Dec 2025; Carsten Brunn named Chairman in Oct 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000063/0001453687-26-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368726000063/rnac-20260309.htm
  HTML page:      https://secwatch.observer/filing/0001453687-26-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer